Jeffrey Greenberg/Education Images/Universal Images Group via Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Democrats are mulling including a provision to negotiate drug prices in an infrastructure bill.
Savings on government spending on prescription drugs could help pay for the infrastructure projects.
The government could save as much as $345 billion, according to the Congressional Budget Office.
Congressional Democrats want to crack down on drug prices to help pay for President Joe Biden s infrastructure package, according to several lawmakers, including House Speaker Nancy Pelosi.
Such a provision would be included in a package that lawmakers hope to pass as early as July 4 if they can gain enough support for it.
Message :
Required fields
Analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in clinical study of LentiGlobin for SCD
bluebird bio has initiated process with regulators to resume clinical studies
Company to hold conference call and webcast today, March 10, 2021, 8:00 AM EST
bluebird bio, Inc. (Nasdaq: BLUE) announced today that based on the analyses completed to date, it is very unlikely the Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) reported in its Phase 1/2 (HGB-206) study of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) was related to the BB305 lentiviral vector (LVV).
“In addition to our earlier findings of several well-known genetic mutations and gross chromosomal abnormalities commonly observed in AML in this patient, our latest analyses identified the integration site for the vector within a gene called VAMP4. VAMP4 has no known association with the development of AML nor with proces
Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes
1c
The study has been designed to define parameters for the upcoming Phase 3 trial planned for 2022
This study follows the promising results of the proof-of-concept Phase 1 trial announced on September 15, 2020
Regulatory News:
Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases, announced today the initiation of a Phase 2 study in type 1 diabetes (T1D). The purpose of the study is to confirm and optimize the safety and efficacy of M1Pram in comparison with insulin lispro (Humalog
Clinical trials to test research showing NZ milk can help in Covid-19 fight
10 Mar, 2021 04:00 PM
3 minutes to read
Dr Rod Claycomb, founder of Hamilton s Quantec, and chief executive Raewyn McPhillips. Photo / Supplied
A Hamilton biotech company is to start clinical trials after research showed its New Zealand milk-derived patented ingredient is effective in Covid-19 protection. Quantec said research, completed by an independent US laboratory, showed its ingredient IDP (Immune Defence Proteins) had the ability to protect cells from Covid-19, but may also reduce the severity of the virus symptoms, a key concern for sufferers of long Covid .
Chief executive Raewyn McPhillips said the clinical trials would likely be held in New Zealand and China.
Perflow Medical Announces the First Clinical Use of the Cascade 17 Dynamic Non-Occlusive Remodeling Net
17 Non-Occlusive Remodeling Net. Expanding the Cascade product family, the Cascade
17 optimizes non-occlusive support of distal and tortuous vessel anatomy during coil embolization of intracranial aneurysms of smaller vessels. The Cascade
17 is the latest addition to Perflow s portfolio of neurovascular devices based on a novel proprietary technology platform, the CEREBRAL NET, which includes the Stream Dynamic Neuro-Thrombectomy Net (Stream Net). Early clinical experience with the Cascade
17 is extremely promising and further expands the range of brain vessels that can now be treated with Perflow s unique CEREBRAL NET technology. The non-occlusive net design enables continuous blood flow during cerebral aneurysm repair and coiling, which maintains appropriate perfusion and may improve patient outcomes.